AU2019321588B2 - Diagnostic and therapeutic methods for the treatment of breast cancer - Google Patents

Diagnostic and therapeutic methods for the treatment of breast cancer

Info

Publication number
AU2019321588B2
AU2019321588B2 AU2019321588A AU2019321588A AU2019321588B2 AU 2019321588 B2 AU2019321588 B2 AU 2019321588B2 AU 2019321588 A AU2019321588 A AU 2019321588A AU 2019321588 A AU2019321588 A AU 2019321588A AU 2019321588 B2 AU2019321588 B2 AU 2019321588B2
Authority
AU
Australia
Prior art keywords
score
breast cancer
induced
pathway activity
repressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019321588A
Other languages
English (en)
Other versions
AU2019321588A1 (en
Inventor
Anneleen Daemen
Ciara METCALFE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2019321588A1 publication Critical patent/AU2019321588A1/en
Assigned to GENENTECH, INC. reassignment GENENTECH, INC. Request for Assignment Assignors: F. HOFFMAN-LA ROCHE AG
Application granted granted Critical
Publication of AU2019321588B2 publication Critical patent/AU2019321588B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Primary Health Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AU2019321588A 2018-08-17 2019-08-16 Diagnostic and therapeutic methods for the treatment of breast cancer Active AU2019321588B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719545P 2018-08-17 2018-08-17
US62/719,545 2018-08-17
PCT/US2019/046814 WO2020037203A2 (en) 2018-08-17 2019-08-16 Diagnostic and therapeutic methods for the treatment of breast cancer

Publications (2)

Publication Number Publication Date
AU2019321588A1 AU2019321588A1 (en) 2021-03-04
AU2019321588B2 true AU2019321588B2 (en) 2026-02-12

Family

ID=67809706

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019321588A Active AU2019321588B2 (en) 2018-08-17 2019-08-16 Diagnostic and therapeutic methods for the treatment of breast cancer

Country Status (11)

Country Link
US (2) US11081236B2 (https=)
EP (1) EP3837548A2 (https=)
JP (1) JP7571006B2 (https=)
KR (1) KR102754524B1 (https=)
CN (1) CN113490850B (https=)
AU (1) AU2019321588B2 (https=)
CA (1) CA3109090A1 (https=)
IL (1) IL280707B2 (https=)
MX (1) MX2021001857A (https=)
TW (1) TW202022124A (https=)
WO (1) WO2020037203A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180098963A1 (en) * 2016-10-11 2018-04-12 Duke University Lasofoxifene treatment of breast cancer
CA3109090A1 (en) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
MX2022000279A (es) 2019-07-07 2022-02-03 Olema Pharmaceuticals Inc Regimenes de antagonistas del receptor de estrogeno.
KR20220113695A (ko) * 2019-12-09 2022-08-16 사노피 7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태
CN115175679A (zh) * 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法
TWI800827B (zh) 2020-05-12 2023-05-01 美商建南德克公司 使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌
CN111893112A (zh) * 2020-08-12 2020-11-06 上海尤里卡信息科技有限公司 胃癌肿瘤标志物及其应用
CN114105977B (zh) * 2020-08-28 2023-09-01 先声再明医药有限公司 雌激素受体调节剂化合物及其用途
JP7830464B2 (ja) * 2020-11-23 2026-03-16 サノフイ 乳がんにおける内分泌療法のモニタリングに使用するためのｅｒ制御遺伝子のパネル
EP4267578A4 (en) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
WO2022166983A1 (zh) * 2021-02-08 2022-08-11 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
JP2024506385A (ja) * 2021-02-16 2024-02-13 ジェネンテック， インコーポレイテッド Ｇｄｃ－９５４５及びｇｄｃ－００７７を含む併用療法を使用する乳がんの治療
MX2023009374A (es) 2021-02-16 2023-08-16 Genentech Inc Tratamiento de cancer de mama mediante el uso de tratamientos conjuntos que comprenden gdc-9545 y abemaciclib o ribociclib.
JP2024506347A (ja) 2021-02-16 2024-02-13 ジェネンテック， インコーポレイテッド Ｇｄｃ－９５４５およびイパタセルチブを含む併用療法を使用する乳がんの処置
US11919879B2 (en) 2021-06-16 2024-03-05 Celgene Corporation Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases
CN117813288A (zh) * 2021-07-15 2024-04-02 西藏海思科制药有限公司 芳氨基衍生物雌激素受体调节剂及其用途
WO2023018197A1 (ko) * 2021-08-09 2023-02-16 고려대학교 산학협력단 자기공명영상과 rna 유전자 정보를 이용한 유방암 관련 정보제공 방법
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
CN119013252A (zh) * 2022-04-15 2024-11-22 赛诺菲 取代的6,7-二氢-5h-苯并[7]轮烯衍生物，用于其制备的方法及其治疗用途
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2024015506A1 (en) * 2022-07-14 2024-01-18 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024076633A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
IL320004A (en) * 2022-10-05 2025-06-01 Olema Pharmaceuticals Inc Methods of treating estrogen receptor-mediated disorders
WO2025096907A1 (en) * 2023-11-01 2025-05-08 The Children's Medical Center Corporation Methods and compositions for immunosuppressant resistant cellular therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015038682A1 (en) * 2013-09-11 2015-03-19 bio Theranostics, Inc. Predicting breast cancer recurrence
US20150347672A1 (en) * 2012-12-26 2015-12-03 Koninklijke Philips N.V. Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
JP2005512510A (ja) * 2001-05-16 2005-05-12 ノバルティス アクチエンゲゼルシャフト 予後および治療標的として乳癌で発現される遺伝子
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
BRPI0414553A (pt) * 2003-09-19 2006-11-07 Arcturus Bioscience Inc previsão do resultado de tratamento contra o cáncer de mama
EP2195467B1 (en) * 2007-09-06 2016-12-14 bioTheranostics, Inc. Tumor grading and cancer prognosis in breast cancer
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
SG11201405918XA (en) 2012-03-20 2014-10-30 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9169207B2 (en) * 2012-03-27 2015-10-27 Incuron, Llc Curaxins for use in treating carcinogen-induced cancer
US10175240B2 (en) * 2012-08-23 2019-01-08 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
EP2912033A4 (en) 2012-10-24 2016-09-14 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-MEDIATED ILLNESSES
WO2014066692A1 (en) 2012-10-24 2014-05-01 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating estrogen-related medical disorders
JP2016517420A (ja) 2013-03-14 2016-06-16 セラゴン ファーマシューティカルズ， インク． 多環式エストロゲン受容体モジュレーター及びその使用
FI3834824T3 (fi) * 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
JP7065610B6 (ja) * 2014-10-24 2022-06-06 コーニンクレッカ フィリップス エヌ ヴェ 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測
KR102785474B1 (ko) * 2014-12-18 2025-03-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
US10399939B2 (en) 2015-11-09 2019-09-03 Genentech, Inc. Tetrahydronaphthalene estrogen receptor modulators and uses thereof
CN109362222B (zh) 2016-02-05 2021-03-19 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
LT3416962T (lt) 2016-02-15 2021-07-12 Sanofi 6,7-dihidro-5h-benzo[7]anuleno dariniai kaip estrogenų recepptoriaus moduliatoriai
AU2017239348B2 (en) 2016-03-25 2020-03-12 Luoxin Healthcare Science and Technology Development (Beijing) Ltd. Substituted-indole compounds as estrogen receptor down-regulators
JP7018026B2 (ja) 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
US20170362228A1 (en) 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
TWI735681B (zh) 2016-10-24 2021-08-11 瑞典商阿斯特捷利康公司 化合物
US10774081B2 (en) 2016-10-28 2020-09-15 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Indolo substituted piperidine compound as estrogen receptor down-regulator
ES3039455T3 (en) 2016-11-17 2025-10-21 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
CA3109090A1 (en) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150347672A1 (en) * 2012-12-26 2015-12-03 Koninklijke Philips N.V. Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions
WO2015038682A1 (en) * 2013-09-11 2015-03-19 bio Theranostics, Inc. Predicting breast cancer recurrence

Also Published As

Publication number Publication date
KR102754524B1 (ko) 2025-01-13
KR20210046031A (ko) 2021-04-27
CN113490850B (zh) 2024-12-06
US20200082944A1 (en) 2020-03-12
JP7571006B2 (ja) 2024-10-22
IL280707B1 (en) 2025-11-01
IL280707A (en) 2021-03-25
IL280707B2 (en) 2026-03-01
CA3109090A1 (en) 2020-02-20
US11081236B2 (en) 2021-08-03
MX2021001857A (es) 2021-10-13
CN113490850A (zh) 2021-10-08
WO2020037203A3 (en) 2020-03-26
WO2020037203A2 (en) 2020-02-20
US11676731B2 (en) 2023-06-13
US20220044819A1 (en) 2022-02-10
JP2021533787A (ja) 2021-12-09
TW202022124A (zh) 2020-06-16
AU2019321588A1 (en) 2021-03-04
EP3837548A2 (en) 2021-06-23

Similar Documents

Publication Publication Date Title
AU2019321588B2 (en) Diagnostic and therapeutic methods for the treatment of breast cancer
US20240200146A1 (en) Diagnostic and therapeutic methods for cancer
US11447830B2 (en) Gene signatures to predict drug response in cancer
CN105611940A (zh) 诊断方法和用于治疗成胶质细胞瘤的组合物
WO2017180581A1 (en) Diagnostic and therapeutic methods for cancer
US20240068047A1 (en) Use of sdha as a prognostic marker and therapeutic target in uveal melanoma
CN114901284A (zh) 用细胞周期蛋白依赖性激酶7(cdk7)抑制剂治疗生物标志物鉴定的患者的癌症的方法
US20200330467A1 (en) Method and pharmaceutical compositions for the treatment of multiple myeloma
WO2014074785A1 (en) Methods of predicting outcome and treating breast cancer
EP4055193A1 (en) Iron-score and in vitro method for identifying high risk dlbcl subjects and therapeutic uses and methods
US20140275201A1 (en) Identification of cancer stem cell markers and use of inhibitors thereof to treat cancer
KR20250111349A (ko) 암 치료 개선을 위한 조성물 및 방법
JP2015511598A (ja) Ｐａｋ１阻害剤を用いて黒色腫を治療する方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GENENTECH, INC.

Free format text: FORMER APPLICANT(S): F. HOFFMAN-LA ROCHE AG

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JAN 2026